Onco-Carbide

Hydroxycarbamide

Method of action: Antitumour, Cytostatic

Treatment option: Carcinoma, Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia In Children, Cancer, Cancer,Ovarian, Acute Chest Syndrome, Choriocarcinoma

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Onco-Carbide

Property	Description
Active Ingredient	Hydroxycarbamide (Hydroxyurea)
Form	Oral Capsules or Tablets
Pharmacological Class	Antineoplastic Agent / Antimetabolite
Origin	Synthetic Small Molecule
Route of Administration	Oral

Onco-Carbide is a prescription-only medicine containing the sole active ingredient Hydroxycarbamide, a compound also widely known as Hydroxyurea. This drug is classified as an antineoplastic agent, placing it within the broad category of medicines used to manage conditions characterized by rapid or abnormal cell growth. More specifically, its function is categorized as an antimetabolite, reflecting its mechanism of interfering with metabolic processes essential for cell proliferation. It has an established role in cytoreductive therapy.

Classification and Composition

Onco-Carbide is defined as a single-ingredient product and is fundamentally a synthetic derivative of urea, specifically a monohydroxyl-substituted urea derivative. The medicine is supplied for patient use as an oral capsule or tablet, making oral ingestion its primary route of administration. This positioning of the drug as an oral option offers a distinctive route of convenience compared to therapies requiring intravenous administration. Popular brands containing this active ingredient include Hydrea and Siklos.

Antimetabolite Action and General Purpose

Its general purpose is to function as a cytoreductive treatment by controlling the overproduction of cells, particularly within the bone marrow, and to modify the structure of red blood cells. As an antimetabolite, its primary function is to inhibit a key enzyme necessary for the assembly of DNA synthesis, thereby arresting the growth of fast-dividing cells. The compound's core action, the suppression of cellular multiplication, is recognized for its role in disease management.

In addition to its role as an antineoplastic agent, Onco-Carbide possesses a unique function as an antisickling agent, which widens its general therapeutic utility. This secondary mechanism involves inducing the production of fetal hemoglobin (HbF), a protein that helps keep red blood cells flexible. Consequently, the general benefit of the medicine is two-fold: reducing excessive cell counts and promoting better-functioning red blood cells.

Regulatory References

What side effects are possible with Onco-Carbide?

Possible Side Effects and Safety Information for Onco-Carbide (Carboplatin)

Onco-Carbide is associated with a specific safety profile, primarily characterized by toxicities affecting the blood, nervous system, and immune response. Regulatory bodies issue warnings to ensure appropriate management of these risks.

Serious and Clinically Significant Adverse Reactions

Myelosuppression: This is the primary dose-limiting toxicity and is dose-related. It involves a severe decrease in blood cell counts, including neutropenia (low white blood cells, increasing infection risk), thrombocytopenia (low platelets, increasing bleeding risk), and anemia (low red blood cells). This can be severe and may result in serious or fatal infections or hemorrhage.
Hypersensitivity Reactions: Anaphylactic-like reactions, which can be life-threatening, have been reported and may occur rapidly—within minutes of administration. The risk is notably increased in patients who have received a high number of treatment cycles (e.g., six or more) or who have prior exposure to platinum-based therapies.
Embryo-Fetal Toxicity: Onco-Carbide can cause fetal harm when administered to a pregnant patient. Women of childbearing potential are required to use effective contraception.

Common Side Effects

Commonly reported non-hematologic side effects often involve the gastrointestinal and nervous systems. These may include nausea and vomiting (often managed with pre-treatment antiemetics), peripheral neuropathy (numbness, tingling, or pain in the hands or feet), ototoxicity (hearing loss or ringing in the ears), and alopecia (hair loss).

Safety Monitoring and Restrictions

Administration must be overseen by a qualified physician experienced in cancer chemotherapy. Regular monitoring of complete blood counts is mandatory before each treatment cycle, and as clinically indicated, to detect and manage myelosuppression. Due to chemical reactivity, needles or infusion sets containing aluminum must be avoided during preparation and administration.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for Onco-Carbide (Hydroxycarbamide) defines the overdose profile primarily by the risk of profound myelosuppression, which is a potentially life-threatening hematologic outcome. This condition involves the severe reduction of white blood cells (leukopenia) and platelets (thrombocytopenia).

Officially documented clinical manifestations of overdose also include acute cutaneous and mucocutaneous toxicity. These presentations involve the rapid onset of painful sores or ulcers in the mouth and throat, as well as severe inflammation, redness, scaling, and swelling on the hands and feet.

Immediate medical attention is mandatory for any suspected overdose. Emergency services must be contacted immediately if the individual experiences critical signs such as collapse, seizure activity, or acute respiratory distress. Hospitalization is required for continuous monitoring and management.

It is officially stated that no specific antidote is known for this overdose. Management is entirely supportive and symptomatic. This includes rigorous monitoring of blood counts and the potential use of blood product transfusions to correct any severe hematologic deficits. Patients with severe renal impairment are a population noted in official labeling as requiring increased caution due to potential toxic accumulation.

Therapeutic Uses of Onco-Carbide

What Onco-Carbide Treats: Main Uses and Benefits

Onco-Carbide (Hydroxycarbamide/Hydroxyurea) is applied across domains where additional symptomatic support is needed in the long-term management of specific, chronic blood disorders and as a supportive agent in certain cancer treatments. The core therapeutic focus is applied in managing symptoms related to systemic imbalance and helps manage symptoms associated with acute or disruptive episodes.

The medication is commonly used to manage Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Chronic Myeloid Leukemia (CML), as well as Sickle Cell Disease (SCD) in both adults and children, and certain squamous cell carcinomas of the head and neck.

In clinical settings that involve recurrent, episodic manifestations of SCD, such as frequent vaso-occlusive (pain) crises and episodes of Acute Chest Syndrome (ACS), the drug is considered relevant. The patient benefit is considered relevant: it provides support that helps address symptom clusters that may become intense or disruptive.

“It provides support that helps ease the overall symptom burden, particularly during difficult episodes.”

Quick Fact: Relief for Vaso-occlusive Crises

Onco-Carbide supports patients by addressing the symptoms linked to organ-specific functional stress, which assists with the goal of managing symptoms that interfere with daily functioning and may assist with the overall goal of minimizing transfusion reliance.

Eligibility and Restrictions for Use

Who can and cannot use Onco-Carbide?

Onco-Carbide (Hydroxycarbamide) use is strictly governed by population eligibility rules defined in official regulatory documents, focusing on absolute prohibitions and conditional use.

Absolute Contraindications

The medicine must not be used by patients with a history of hypersensitivity to hydroxyurea or any formulation component. It is strictly contraindicated in individuals with markedly depressed bone marrow function and for those who are actively breastfeeding. Severe renal or severe hepatic impairment may also prohibit use, depending on the regulatory region.

Age and Conditional Use

The drug is approved for adults and for children older than 2 years for specific indications, with some formulations approved for children as young as six months. Elderly patients may be more sensitive and may require closer monitoring. For individuals with moderate renal impairment (CrCl leq60 mL/min), use is conditional and requires a 50% dose reduction.

Reproductive and Other Restrictions

Onco-Carbide is not recommended during pregnancy due to the risk of fetal harm. Females of reproductive potential must use effective contraception for six months following the last dose, and males for one year. Patients must avoid taking live vaccines and must not use specific antiviral drugs (didanosine and stavudine) concurrently.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Onco-Carbide (Hydroxycarbamide) interaction patterns are defined by pharmacodynamic potentiation and specific prohibitions documented in regulatory labeling.

Co-administration with Live Vaccines is formally avoided (prohibited) due to the risk of potentiating virus replication and increasing the adverse reaction risk, which may lead to severe infection. The combination of Onco-Carbide with the antiretroviral drugs Didanosine and Stavudine is associated with severe or fatal toxicities, including pancreatitis and hepatotoxicity, and should be avoided.

Interaction Type	Interacting Agent	Official Outcome
Pharmacodynamic Potentiation	Cytotoxic Chemotherapies	May potentiate myelosuppressive activity.
Pharmacodynamic Potentiation	Interferon Therapy	Increased risk for cutaneous vasculitic toxicities (e.g., ulcerations).
Pharmacodynamic Potentiation	Radiotherapy	May increase specific adverse reactions; administration is typically initiated seven days before concurrent irradiation begins.

Specific population notes exist: HIV-infected patients face a heightened risk for enhanced toxicities when using the specified antiretroviral combinations. Patients with prior local irradiation exposure may experience radiation recall upon receiving the medicine.

Furthermore, Onco-Carbide causes analytical interference with specific enzymatic assays for Uric Acid, Urea, and Lactic Acid, potentially yielding falsely elevated laboratory results, and may falsely elevate sensor glucose readings from certain continuous monitoring systems.

Mechanism of Action

Inhibition of DNA Synthesis and Cell Cycle Arrest

The primary action of Onco-Carbide is achieved by inactivating Ribonucleotide Reductase ( RNR), a critical enzyme that creates the building blocks for DNA. The drug acts as a radical scavenger to quench the enzyme’s active site, depleting the pool of deoxyribonucleotides (dNTPs) required for cell division. This molecular blockade leads to S-phase cell cycle arrest and results in the physiological consequence of cytoreduction, slowing the proliferation of rapidly dividing cells in the bone marrow.

Modulation of gamma-Globin Gene Expression

The second distinct mechanism involves influencing the composition of red blood cells. The molecule acts as a mild Nitric Oxide (NO) donor, activating the sGC/ cGMP pathway in blood cell precursors. This signaling cascade modulates gene expression by suppressing factors (like BCL11A) that normally silence the gamma-globin gene, leading to the sustained production of Fetal Hemoglobin ( HbF). The presence of HbF stabilizes the internal structure of the red cell and contributes to microvascular fluidity (reduced blood cell adhesion). The resulting physiological change linked to HbF induction is time-dependent and requires the turnover of the entire circulating red blood cell population, representing a biological constraint on the mechanism's uniformity.

Dosage and Administration Information

Onco-Carbide (Hydroxycarbamide) is strictly an oral medicine supplied as capsules or scored tablets for daily ingestion. The dose is not a fixed amount but is precisely determined by calculation based on the patient's actual or ideal body weight, whichever is less.

Standard Dosing Regimens

Therapy is administered once daily, with schedules varying based on the condition. For continuous use in chronic conditions, initial dosing is typically in the range of 20 to 30 mg/kg per day. For Sickle Cell Disease (SCD), the initial daily dose is 15 mg/kg, followed by gradual dose increases (titration) over intervals of 8 to 12 weeks until the maximum tolerated amount is reached, which may be up to 35 mg/kg/day. An alternative, intermittent schedule of 80 mg/kg every third day is employed for specific regimens.

Administration and Adjustments

The medicine should be taken at the same time each day; the timing relative to meals is not generally restrictive. Capsules must be swallowed whole and must not be opened or chewed, but tablets can be split or dispersed in a small amount of water for administration. A mandatory procedural requirement is a 50% dose reduction when the patient has impaired kidney function (CrCl < 60 mL/min); for patients on dialysis, the dose should be taken after the hemodialysis session. If a dose is missed, a double dose must not be taken.

Recent Clinical Evidence

Research Evidence for Sickle Cell Disease (SCD)

Research related to Onco-Carbide in Sickle Cell Disease (SCD) includes several Randomized Controlled Trials (RCTs), a well-established type of clinical study, alongside large-scale Observational Studies. Studies evaluated patient outcomes, which included episodic or acute changes such as the frequency of painful vaso-occlusive crises and Acute Chest Syndrome (ACS) events, as well as the requirement for blood transfusions. Researchers also explored changes in the biomarker fetal hemoglobin (HbF). While core research has explored these outcomes over intermediate time intervals, the research highlights that long-term clinical outcomes primarily rely on observational settings.

Research Evidence for Myeloproliferative Neoplasms (MPNs)

For Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV) and Essential Thrombocythemia (ET), Onco-Carbide was evaluated in clinical trials focusing on high-risk Adults. Studies examined the assessment of hematological response criteria, evaluating how blood cell counts compared to predefined target ranges. Research reported that measurements of the incidence of thrombotic events (blood clots) were a key focus. Comparative evidence examining all treatment modalities remains limited.

Long-Term Studies and Follow-Up Data

The core RCTs that are foundational to the research typically had follow-up durations that were limited to months. Therefore, observational studies and patient registries extend this knowledge, providing context for the durability of measured effects over multiple years.

Evidence in Special Populations

Research has explored the use of Onco-Carbide in specific populations, including children with SCD for outcomes like stroke prevention, and older adults with high-risk MPNs. However, data for certain groups remain insufficient, meaning the results apply only to the populations specifically studied.

Research Gaps and Uncertainties

Despite foundational research, several areas remain where certainty is low. A key gap is the limited information for long-term outcomes derived from Randomized Controlled Trials (RCTs). Additionally, the development of resistance or intolerance in some patients is a challenge, and studies focusing on episodes where symptoms become more noticeable due to treatment challenges remain a subject of research.

Key Studies & References NIH National Cancer Institute Drug Information: Hydroxyurea (General Drug Details)

Frequently Asked Questions (FAQ)

Common questions about Onco-Carbide (FAQ)

Q: What is Onco-Carbide and what is it approved for?

A: Onco-Carbide is a medication that belongs to a class of drugs called antimetabolites. It is approved by the U.S. Food and Drug Administration (FDA) to be used to treat certain conditions. These approved uses include:

Chronic Myeloid Leukemia (CML): A specific type of blood cancer.
Squamous Cell Carcinomas of the Head and Neck: Used in combination with radiation therapy.
Sickle Cell Anemia: To help reduce the frequency of painful crises and the need for blood transfusions in adult and pediatric patients (9 months of age and older) with recurrent moderate to severe painful crises.

Q: How does Onco-Carbide work in the body?

A: Onco-Carbide is understood to function by interfering with the synthesis of DNA within cells. This action may slow down the reproduction of rapidly dividing cells, such as certain cancer cells. In the case of sickle cell anemia, the medication may influence the production of a type of hemoglobin called fetal hemoglobin (HbF).

Q: What are some possible side effects associated with Onco-Carbide?

A: The most common and serious reported side effect of Onco-Carbide is bone marrow suppression. This may be linked to decreased production of blood cells, which can lead to:

Increased risk of infection: Due to low white blood cell counts (leukopenia).
Increased risk of bleeding or bruising: Due to low platelet counts (thrombocytopenia).
Anemia: Due to low red blood cell counts.

Other common side effects reported in studies include:

Gastrointestinal issues like nausea, vomiting, or diarrhea.
Skin and nail changes.
Development of mouth sores.

Regular monitoring of blood counts is typically required during treatment to check for these effects.

Q: Can Onco-Carbide be taken with other medications?

A: Onco-Carbide has the potential to interact with other medications, including certain antiretroviral drugs used to treat HIV, as well as some vaccines. Taking Onco-Carbide with other drugs that can affect bone marrow or cause liver problems may increase the risk of certain side effects.

It is important to inform a healthcare provider of all prescription drugs, over-the-counter medicines, and supplements currently being taken to properly assess potential interactions and risks.

Q: What precautions should be taken when handling Onco-Carbide capsules?

A: As with many chemotherapy agents, precautions are advised when handling Onco-Carbide. Handling the drug, or any powder residue from an opened or broken capsule, may pose a risk. It is generally recommended that individuals wear disposable gloves when handling the drug container or the medicine itself. It is also important to wash hands thoroughly before and after handling the capsules. If powder comes into contact with the skin or eyes, wash the area immediately.

It is important not to open the capsules or crush the tablets; the medicine should be taken exactly as prescribed.

How should Onco-Carbide be stored and disposed of?

How to Store and Dispose of Onco-Carbide

Onco-Carbide (Hydroxycarbamide/Hydroxyurea) is a hazardous drug that requires specific handling and storage.

Storage Conditions

Temperature: Store at Controlled Room Temperature only, between 20 C to 25 C (68 F to 77 F). Do not store above 25 C.

Container and Protection: Keep the medicine in the original container and ensure the container is tightly closed to protect it from light and moisture.

Safety: Keep this medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired Onco-Carbide must be disposed of in accordance with local requirements for hazardous waste. The medicine must not be flushed down the toilet or poured into wastewater due to its classification as an antineoplastic agent. If capsule powder is spilled, it must be carefully cleaned up with a damp cloth and disposed of as hazardous waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Italy

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z